The Experts below are selected from a list of 187944 Experts worldwide ranked by ideXlab platform
Qihui Wang - One of the best experts on this subject based on the ideXlab platform.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Zhou Tong-qua, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Feng Gao, Yan ChaiAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Yan Chai, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Zhou Tong, Huabing YangAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV. The isolation and characterization of glycoprotein-specific Monoclonal Antibodies from a patient with Rift Valley fever (RVF) provide insights into the humoral immune responses elicited by the RVF virus as well as the therapeutic potential of antibody-based strategies.
Yan Chai - One of the best experts on this subject based on the ideXlab platform.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Zhou Tong-qua, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Feng Gao, Yan ChaiAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Yan Chai, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Zhou Tong, Huabing YangAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV. The isolation and characterization of glycoprotein-specific Monoclonal Antibodies from a patient with Rift Valley fever (RVF) provide insights into the humoral immune responses elicited by the RVF virus as well as the therapeutic potential of antibody-based strategies.
Huabing Yang - One of the best experts on this subject based on the ideXlab platform.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Yan Chai, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Zhou Tong, Huabing YangAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV. The isolation and characterization of glycoprotein-specific Monoclonal Antibodies from a patient with Rift Valley fever (RVF) provide insights into the humoral immune responses elicited by the RVF virus as well as the therapeutic potential of antibody-based strategies.
Jianxun Qi - One of the best experts on this subject based on the ideXlab platform.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Zhou Tong-qua, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Feng Gao, Yan ChaiAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Yan Chai, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Zhou Tong, Huabing YangAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV. The isolation and characterization of glycoprotein-specific Monoclonal Antibodies from a patient with Rift Valley fever (RVF) provide insights into the humoral immune responses elicited by the RVF virus as well as the therapeutic potential of antibody-based strategies.
Hui Zeng - One of the best experts on this subject based on the ideXlab platform.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Zhou Tong-qua, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Feng Gao, Yan ChaiAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV.
-
neutralization mechanism of human Monoclonal Antibodies against rift valley fever virus
Nature microbiology, 2019Co-Authors: Jianxun Qi, Zhennan Zhao, Yan Chai, Qihui Wang, Zhihai Chen, Yan Wu, Hui Zeng, Zhou Tong, Huabing YangAbstract:Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of Monoclonal Antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-specific Monoclonal Antibodies exhibited much higher neutralizing activities in vitro and protection efficacies in mice against RVFV infection, compared to the Gc-specific Monoclonal Antibodies. The Gn Monoclonal Antibodies were found to interfere with soluble Gn binding to cells and prevent infection by blocking the attachment of virions to host cells. Structural analysis of Gn complexed with four Gn-specific Monoclonal Antibodies resulted in the definition of three antigenic patches (A, B and C) on Gn domain I. Both patches A and B are major neutralizing epitopes. Our results highlight the potential of antibody-based therapeutics and provide a structure-based rationale for designing vaccines against RVFV. The isolation and characterization of glycoprotein-specific Monoclonal Antibodies from a patient with Rift Valley fever (RVF) provide insights into the humoral immune responses elicited by the RVF virus as well as the therapeutic potential of antibody-based strategies.
